| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 208 |
| 1 | PREDNISONE | 145 |
| 2 | CYCLOPHOSPHAMIDE | 75 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 75 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 75 |
| 5 | TACROLIMUS | 75 |
| 6 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 74 |
| 7 | TACROLIMUS OINTMENT 0.1% | 74 |
| 8 | MYCOPHENOLATE MOFETIL | 71 |
| 9 | BENDAMUSTINE HCL | 52 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BENDAMUSTINE HCL | 52 | 0.0033 |
| 1 | CAPLACIZUMAB | 4 | 0.0022 |
| 2 | ELRANATAMAB-BCMM | 2 | 0.0017 |
| 3 | BENDAMUSTINE HYDROCHLORIDE | 13 | 0.0015 |
| 4 | REMDESIVIR | 16 | 0.0012 |
| 5 | RITUXIMAB | 208 | 0.0010 |
| 6 | ALBUMIN HUMAN | 4 | 0.0008 |
| 7 | FINGOLIMOD HYDROCHLORIDE | 4 | 0.0008 |
| 8 | CHLORAMBUCIL | 3 | 0.0008 |
| 9 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] | 16 | 0.0012 |
| 1 | CD20-directed Cytolytic Antibody [EPC] | 220 | 0.0007 |
| 2 | Echinocandin Antifungal [EPC] | 3 | 0.0004 |
| 3 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 4 | Alkylating Drug [EPC] | 76 | 0.0003 |
| 5 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 4 | 0.0003 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 7 | Antimetabolite Immunosuppressant [EPC] | 4 | 0.0002 |
| 8 | CD52-directed Cytolytic Antibody [EPC] | 3 | 0.0002 |
| 9 | Corticosteroid [EPC] | 199 | 0.0002 |